Esperion Therapeutics (NASDAQ:ESPR) Price Target Cut to $4.00 by Analysts at Needham & Company LLC

Esperion Therapeutics (NASDAQ:ESPR) had its target price lowered by Needham & Company LLC from $5.00 to $4.00 in a research report released on Wednesday morning,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

A number of other brokerages have also issued reports on ESPR. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price objective on shares of Esperion Therapeutics in a report on Friday, April 25th. The Goldman Sachs Group cut their target price on shares of Esperion Therapeutics from $4.00 to $3.00 and set a “neutral” rating for the company in a research note on Thursday, April 17th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $4.00 price target (down previously from $7.00) on shares of Esperion Therapeutics in a research note on Tuesday, February 11th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $6.25.

Esperion Therapeutics Stock Performance

ESPR opened at $0.80 on Wednesday. The stock has a market cap of $158.16 million, a price-to-earnings ratio of -1.25 and a beta of 0.75. The firm’s fifty day moving average is $1.24 and its 200 day moving average is $1.88. Esperion Therapeutics has a fifty-two week low of $0.73 and a fifty-two week high of $3.94.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.03). The firm had revenue of $65.00 million during the quarter, compared to analyst estimates of $54.97 million. On average, equities research analysts predict that Esperion Therapeutics will post -0.29 earnings per share for the current year.

Institutional Investors Weigh In On Esperion Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Cibc World Markets Corp purchased a new position in shares of Esperion Therapeutics in the 4th quarter worth approximately $39,000. Synergy Asset Management LLC lifted its position in Esperion Therapeutics by 3,496.3% in the first quarter. Synergy Asset Management LLC now owns 31,000 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 30,138 shares during the last quarter. SJS Investment Consulting Inc. purchased a new position in Esperion Therapeutics during the fourth quarter worth $55,000. Private Advisor Group LLC increased its position in Esperion Therapeutics by 33.2% during the first quarter. Private Advisor Group LLC now owns 40,106 shares of the biopharmaceutical company’s stock valued at $58,000 after acquiring an additional 10,000 shares during the last quarter. Finally, Crestline Management LP purchased a new stake in shares of Esperion Therapeutics in the fourth quarter valued at $63,000. Hedge funds and other institutional investors own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.